Concepts (124)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension, Pulmonary | 13 | 2024 | 439 | 2.860 |
Why?
|
| Vascular Diseases | 2 | 2025 | 155 | 1.000 |
Why?
|
| Bronchopulmonary Dysplasia | 3 | 2024 | 207 | 0.940 |
Why?
|
| Lung Diseases | 2 | 2025 | 384 | 0.900 |
Why?
|
| Hernias, Diaphragmatic, Congenital | 3 | 2024 | 399 | 0.830 |
Why?
|
| Consensus | 1 | 2024 | 644 | 0.720 |
Why?
|
| Lung | 4 | 2025 | 1487 | 0.720 |
Why?
|
| Actigraphy | 2 | 2024 | 45 | 0.440 |
Why?
|
| Hemodynamics | 3 | 2022 | 849 | 0.310 |
Why?
|
| Infant, Newborn | 8 | 2024 | 8273 | 0.280 |
Why?
|
| Pulmonary Artery | 1 | 2020 | 438 | 0.260 |
Why?
|
| SOXF Transcription Factors | 1 | 2024 | 18 | 0.230 |
Why?
|
| Infant | 8 | 2024 | 12602 | 0.230 |
Why?
|
| Child, Preschool | 9 | 2024 | 14145 | 0.220 |
Why?
|
| Registries | 1 | 2020 | 1434 | 0.210 |
Why?
|
| Ductus Arteriosus, Patent | 1 | 2024 | 143 | 0.200 |
Why?
|
| Vasodilator Agents | 3 | 2022 | 202 | 0.190 |
Why?
|
| Exercise | 2 | 2024 | 814 | 0.190 |
Why?
|
| Humans | 21 | 2025 | 125309 | 0.180 |
Why?
|
| Biopsy | 1 | 2024 | 1244 | 0.180 |
Why?
|
| Patient Care Team | 1 | 2024 | 542 | 0.170 |
Why?
|
| Tracheostomy | 1 | 2022 | 196 | 0.170 |
Why?
|
| Vulnerable Populations | 1 | 2021 | 137 | 0.160 |
Why?
|
| Sildenafil Citrate | 2 | 2016 | 55 | 0.160 |
Why?
|
| Infant, Premature | 2 | 2023 | 833 | 0.160 |
Why?
|
| Mitochondrial Diseases | 1 | 2020 | 132 | 0.150 |
Why?
|
| Hyperbilirubinemia, Neonatal | 1 | 2007 | 3 | 0.150 |
Why?
|
| Echocardiography | 2 | 2021 | 1066 | 0.140 |
Why?
|
| Child | 10 | 2024 | 24608 | 0.140 |
Why?
|
| Hemophilia A | 1 | 2007 | 21 | 0.140 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2017 | 38 | 0.140 |
Why?
|
| Collateral Circulation | 1 | 2017 | 41 | 0.140 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2020 | 374 | 0.140 |
Why?
|
| Stenosis, Pulmonary Vein | 1 | 2017 | 19 | 0.140 |
Why?
|
| Polytetrafluoroethylene | 1 | 2017 | 76 | 0.140 |
Why?
|
| Paclitaxel | 1 | 2017 | 130 | 0.130 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2017 | 68 | 0.130 |
Why?
|
| Anemia, Sickle Cell | 1 | 2020 | 331 | 0.130 |
Why?
|
| Prognosis | 3 | 2021 | 4685 | 0.130 |
Why?
|
| Premature Birth | 1 | 2021 | 388 | 0.130 |
Why?
|
| Angioplasty, Balloon | 1 | 2017 | 155 | 0.130 |
Why?
|
| Growth Differentiation Factors | 1 | 2016 | 11 | 0.130 |
Why?
|
| Phenotype | 1 | 2025 | 4269 | 0.120 |
Why?
|
| Disease Progression | 1 | 2021 | 2083 | 0.120 |
Why?
|
| Developmental Disabilities | 1 | 2020 | 715 | 0.120 |
Why?
|
| Carrier Proteins | 1 | 2020 | 1034 | 0.110 |
Why?
|
| Hypotension | 1 | 2016 | 186 | 0.110 |
Why?
|
| Mexican Americans | 1 | 2016 | 202 | 0.110 |
Why?
|
| Prospective Studies | 4 | 2024 | 6140 | 0.110 |
Why?
|
| Pandemics | 1 | 2021 | 1113 | 0.110 |
Why?
|
| Female | 11 | 2024 | 66791 | 0.110 |
Why?
|
| Cardiac Catheterization | 3 | 2024 | 633 | 0.110 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2014 | 223 | 0.100 |
Why?
|
| STAT3 Transcription Factor | 1 | 2014 | 218 | 0.100 |
Why?
|
| Autoimmune Diseases | 1 | 2014 | 252 | 0.100 |
Why?
|
| Retrospective Studies | 4 | 2024 | 16360 | 0.100 |
Why?
|
| Walk Test | 2 | 2024 | 24 | 0.090 |
Why?
|
| Adolescent | 6 | 2024 | 19424 | 0.090 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2014 | 442 | 0.090 |
Why?
|
| Male | 11 | 2024 | 61531 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2021 | 3602 | 0.080 |
Why?
|
| Mutation | 2 | 2020 | 5903 | 0.070 |
Why?
|
| Pregnancy | 1 | 2021 | 7225 | 0.070 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 5165 | 0.060 |
Why?
|
| Survival Rate | 1 | 2020 | 2049 | 0.060 |
Why?
|
| Sample Size | 1 | 2024 | 86 | 0.060 |
Why?
|
| Age Factors | 1 | 2020 | 2817 | 0.050 |
Why?
|
| Familial Primary Pulmonary Hypertension | 1 | 2023 | 20 | 0.050 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2022 | 50 | 0.050 |
Why?
|
| Anticoagulants | 2 | 2017 | 578 | 0.050 |
Why?
|
| Syndrome | 1 | 2024 | 1121 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2024 | 761 | 0.050 |
Why?
|
| Heart Rate | 1 | 2024 | 592 | 0.050 |
Why?
|
| Respiration, Artificial | 1 | 2024 | 473 | 0.050 |
Why?
|
| Time Factors | 2 | 2024 | 6308 | 0.050 |
Why?
|
| Atrial Function, Left | 1 | 2020 | 27 | 0.040 |
Why?
|
| Dilatation | 1 | 2020 | 66 | 0.040 |
Why?
|
| Logistic Models | 1 | 2024 | 1802 | 0.040 |
Why?
|
| Gestational Age | 1 | 2023 | 1169 | 0.040 |
Why?
|
| Length of Stay | 1 | 2024 | 1310 | 0.040 |
Why?
|
| Heart Atria | 1 | 2020 | 320 | 0.040 |
Why?
|
| Blood Coagulation Disorders, Inherited | 1 | 2007 | 3 | 0.040 |
Why?
|
| Ecchymosis | 1 | 2007 | 11 | 0.040 |
Why?
|
| Heart | 1 | 2022 | 731 | 0.040 |
Why?
|
| Early Medical Intervention | 1 | 2017 | 30 | 0.040 |
Why?
|
| Respiratory Function Tests | 1 | 2017 | 198 | 0.030 |
Why?
|
| Drug-Eluting Stents | 1 | 2017 | 63 | 0.030 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2017 | 91 | 0.030 |
Why?
|
| Radiography, Thoracic | 1 | 2017 | 151 | 0.030 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2017 | 101 | 0.030 |
Why?
|
| Drug Administration Routes | 1 | 2016 | 33 | 0.030 |
Why?
|
| Polysomnography | 1 | 2017 | 145 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2024 | 2908 | 0.030 |
Why?
|
| Growth Differentiation Factor 2 | 1 | 2016 | 3 | 0.030 |
Why?
|
| Young Adult | 1 | 2020 | 9055 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2016 | 143 | 0.030 |
Why?
|
| Epoprostenol | 1 | 2016 | 69 | 0.030 |
Why?
|
| Codon, Nonsense | 1 | 2016 | 131 | 0.030 |
Why?
|
| Coronary Angiography | 1 | 2017 | 449 | 0.030 |
Why?
|
| United States | 1 | 2020 | 10907 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2016 | 554 | 0.030 |
Why?
|
| Warfarin | 1 | 2016 | 117 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2016 | 730 | 0.030 |
Why?
|
| STAT1 Transcription Factor | 1 | 2014 | 73 | 0.030 |
Why?
|
| Hemorrhage | 1 | 2007 | 467 | 0.030 |
Why?
|
| STAT5 Transcription Factor | 1 | 2014 | 88 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2016 | 682 | 0.030 |
Why?
|
| Homozygote | 1 | 2016 | 548 | 0.030 |
Why?
|
| Sulfonamides | 1 | 2016 | 270 | 0.030 |
Why?
|
| Adult | 2 | 2020 | 29528 | 0.030 |
Why?
|
| Anemia | 1 | 2007 | 341 | 0.030 |
Why?
|
| Lung Transplantation | 1 | 2017 | 314 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2022 | 4828 | 0.030 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2014 | 216 | 0.030 |
Why?
|
| Antihypertensive Agents | 1 | 2016 | 415 | 0.030 |
Why?
|
| Aged | 1 | 2020 | 19711 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2007 | 1901 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2017 | 978 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2017 | 12282 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2014 | 1638 | 0.020 |
Why?
|
| Middle Aged | 1 | 2020 | 26741 | 0.020 |
Why?
|
| Risk Factors | 1 | 2024 | 10296 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 2093 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2016 | 3307 | 0.020 |
Why?
|